Nephrol Dial Transplant (2000) 15: 1673-1676
© 2000 European Renal Association-European Dialysis and Transplant Association
Preliminary Report
Prevention of acute rejection with antithymocyte globulin, avoiding corticosteroids, and delaying cyclosporin after renal transplantation
1 Department of Nephrology and Clinical Immunology, Institut de Transplantation et de Recherche en Transplantation (ITERT), 2 Department of Pathology, Nantes University Hospital, Nantes, France
Background. Despite their well-known side-effects, corticosteroids (Cs) are currently used after kidney transplantation. Avoidance of Cs may improve patient quality of life and eventual long-term survival. We report on a regimen using antithymocyte globulin (ATG) and mycophenolate mofetil (MMF) for induction, and cyclosporin (CsA) plus MMF for maintenance treatment of recipients of primary kidney transplantation.
Methods. We studied 11 consecutive, non-sensitized renal transplant patients (nine cadaver and two living donors). Initial immunosuppression consisted of ATG (1.5 mg/kg/day, i.v.) given for 10 days and MMF (1.0 g/b.i.d.). CsA (8 mg/kg, in two divided doses) was started on post-operative day 11. Cs were only allowed in the case of MMF discontinuation, for the treatment of acute rejection, and in the event of recurrence of the primary glomerulonephritis.
Results. All patients completed the entire 10-day ATG course. Main side-effects included fever (>38°C) and serum sickness, observed in 73 and 27% of the patients respectively. The incidence of acute rejection was 27% (three of 11 patients). In two patients with acute rejection, serum sickness was concomitantly diagnosed and renal histology was partially compatible with immune-complex disease. The remaining patient had two episodes of low-grade rejection. All rejection episodes were rapidly reversed. Two patients (18%) were treated with ganciclovir for cytomegalovirus (CMV) infection. Two patients (18%) are currently receiving Cs for recurrence of the native glomerulonephritis and two rejection episodes respectively. All patients are currently alive with functioning kidneys (average follow-up of 8.4 months; average creatinine level of 128 µmol/l).
Conclusion. This pilot study suggests that ATG induction in combination with MMF and delayed introduction of CsA, in the absence of Cs, is not well tolerated in recipients of kidney transplants. An earlier introduction of calcineurin inhibitors and/or a shorter course of ATG may reduce the incidence of fever and serum sickness secondary to ATG.
Keywords: antithymocyte globulin; corticosteroids; cyclosporin; immunosuppression; mycophenolate mofetil; side-effects
Correspondence and offprint requests to: Diego Cantarovich MD, Department of Nephrology and Clinical Immunology, Institut de Transplantation et de Recherche en Transplantation (ITERT), Nantes University Hospital, 30 Boulevard Jean Monnet, F-44093 Nantes, France.